Fate Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.634; its P/E ratio is -2.78; Fate Therapeutics is scheduled to report earnings on May 1, 2024, and the estimated EPS forecast is $-0.48. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 1.68M	$ 1.94M	$ 933.00K	$ 58.98M	$ 44.36M
Gross Profit	$ 1.68M	$ 1.94M	$ 933.00K	$ 58.98M	$ 44.36M
EBIT	$ -44.12M	$ -45.17M	$ -52.76M	$ -18.88M	$ -59.24M
EBITDA	$ -42.13M	$ -43.69M	$ -51.23M	$ -16.98M	-
Net Income Common Stockholders	$ -44.12M	$ -45.17M	$ -52.76M	$ -18.88M	$ -56.36M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 315.18M	$ 349.73M	$ 377.94M	$ 408.90M	$ 436.23M
Total Assets	$ 506.22M	$ 543.79M	$ 584.76M	$ 630.34M	$ 595.54M
Total Debt	$ 103.54M	$ 104.95M	$ 106.35M	$ 107.61M	$ 109.34M
Net Debt	$ -211.64M	$ -244.78M	$ -271.59M	$ -301.28M	$ -326.89M
Total Liabilities	$ 137.80M	$ 141.01M	$ 147.00M	$ 152.86M	$ 705.56M
Stockholders Equity	$ 368.42M	$ 402.78M	$ 437.75M	$ 477.47M	$ 483.94M
Cash Flow	-
Free Cash Flow	$ -36.82M	$ -38.84M	$ -30.69M	$ -32.07M	$ -82.02M
Operating Cash Flow	$ -36.64M	$ -38.27M	$ -28.49M	$ -28.86M	$ -75.35M
Investing Cash Flow	$ 45.35M	$ 24.80M	$ 33.17M	$ 9.34M	$ 53.11M
Financing Cash Flow	$ -180.00K	-	$ 58.00K	$ 207.00K	$ 1.52M

Currency in USD

Fate Therapeutics Earnings and Revenue History

Income Statement >

Fate Therapeutics Debt to Assets

Balance Sheet >

Fate Therapeutics Cash Flow

Cash Flow >

Fate Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing